Zai Lab (NASDAQ:ZLAB) CEO Sells 7,026 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 7,026 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $18.53, for a total value of $130,191.78. Following the transaction, the chief executive officer directly owned 1,203,784 shares of the company’s stock, valued at approximately $22,306,117.52. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Friday, June 26th, Ying Du sold 24,543 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total transaction of $428,520.78.
• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $20.09, for a total transaction of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Trading Up 0.8%

Shares of Zai Lab stock traded up $0.15 during trading hours on Wednesday, reaching $19.15. 686,358 shares of the company’s stock were exchanged, compared to its average volume of 819,753. The stock has a market cap of $2.17 billion, a P/E ratio of -11.82 and a beta of 0.78. The company has a 50 day moving average of $19.19 and a two-hundred day moving average of $18.96. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $41.20.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $99.61 million for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%. As a group, analysts expect that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Citigroup reduced their target price on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. JPMorgan Chase & Co. decreased their target price on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Finally, Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.